Alan CPA - Tyra Biosciences Chief Officer
| TYRA Stock | USD 15.68 0.32 2.00% |
Executive
Alan CPA is Chief Officer of Tyra Biosciences
| Age | 67 |
| Address | 2656 State Street, Carlsbad, CA, United States, 92008 |
| Phone | 619 728 4760 |
| Web | https://tyra.bio |
Tyra Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2021) % which means that it has lost $0.2021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2866) %, meaning that it created substantial loss on money invested by shareholders. Tyra Biosciences' management efficiency ratios could be used to measure how well Tyra Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.36. At present, Tyra Biosciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.3 M, whereas Total Assets are forecasted to decline to about 179.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Paige Mahaney | C4 Therapeutics | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| MD MBA | Molecular Partners AG | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Kevin Brennan | Xilio Development | 54 | |
| Douglas CPA | Century Therapeutics | N/A | |
| Robert Ticktin | Pmv Pharmaceuticals | 62 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| William MD | RAPT Therapeutics | 58 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Michael Naso | Century Therapeutics | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Steve Young | RAPT Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 |
Tyra Biosciences Leadership Team
Elected by the shareholders, the Tyra Biosciences' board of directors comprises two types of representatives: Tyra Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tyra. The board's role is to monitor Tyra Biosciences' management team and ensure that shareholders' interests are well served. Tyra Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tyra Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Sarah Honig, Vice Strategy | ||
| Amy Conrad, Investor Contact | ||
| Douglas MD, Chief Officer | ||
| Hiroomi MD, Chief Officer | ||
| Lynn Scherm, F Director | ||
| Todd Harris, President, CoFounder | ||
| Liz Pagano, Senior Resources | ||
| Robert Hudkins, Chief Officer | ||
| Ali JD, General Secretary | ||
| Daniel Bensen, CoFounder COO | ||
| Alan Fuhrman, Chief Officer | ||
| Piyush Patel, Chief Officer | ||
| Ronald Swanson, Chief Officer | ||
| Alan CPA, Chief Officer |
Tyra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tyra Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 439.64 M | ||||
| Shares Outstanding | 50.6 M | ||||
| Shares Owned By Insiders | 4.77 % | ||||
| Shares Owned By Institutions | 98.92 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 2.19 X | ||||
| EBITDA | (79.59 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Return On Assets (0.20) | Return On Equity (0.29) |
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.